Sai Life Sciences (SLS) is the Hyderabad-based CRO/CDMO darling that works for 17 of the top 20 global pharma giants but still behaves like a stingy landlord who never pays dividends. Market cap ₹17,200 Cr, P/E a jaw-dropping 70x, and not a single paisa to shareholders. They’ve done 200+ discovery programs, 40+ drugs in clinical phases, and expanded labs like there’s no tomorrow. But investors are left asking: is this Divi’s Lab in the making, or another biotech midcap with more hype than free cash flow?
2. Introduction
Sai Life began its journey in 1999 when “outsourcing” in pharma meant Indian chemists working late nights while their US counterparts went golfing. Over 25 years, they’ve built an enviable global client list — literally everyone from Pfizer to Novartis is on their rolodex.
Their positioning is clear: integrated services from drug discovery → clinical development → commercial manufacturing. In plain English: from lab notebook to pill bottle, they’ll do everything — for a fee.
FY24 saw strong growth — sales ₹1,911 Cr (+16%), PAT ₹244 Cr (+107%). And unlike many Indian midcaps, over 98% of their revenue comes from exports, mostly to US/EU. Translation: they’re basically billing in dollars, paying in rupees, and enjoying the forex party.
But here’s the twist: while they’re growing fast, the stock is already priced like a blockbuster drug that hasn’t cleared FDA Phase 3 yet. P/E ~70, EV/EBITDA ~32, Price/Sales ~9. Investors are paying premium prices for future compounding — but will the molecules behave?
3. Business Model – WTF Do They Even Do?
Sai Life operates across two big buckets:
CRO (Contract Research):
Discovery services in chemistry, biology, toxicology.
200+ discovery projects so far.
Facilities in Hyderabad + Boston.
CDMO (Contract Development & Manufacturing):
38 APIs/intermediates under development.
Servicing ~28 commercial drugs (7 are blockbusters).
Plants in India + subsidiaries in USA and Germany.
Revenue Split FY24:
CDMO: 66%
CRO: 34%
Client Split: 90% from regulated markets, 98% exports. So essentially, the Indian entity exists to execute lab work; the money comes from US/EU pharma giants.
Therapy focus: oncology, CNS, inflammation, antivirals — the hottest (and most expensive) categories in global pipelines.
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue (₹ Cr)
496
280
580
77.5%
-14.5%
EBITDA (₹ Cr)
121
26
158
365%
-23.4%
PAT (₹ Cr)
60.5
-14
88
NA
-31.2%
EPS (₹)
2.9
-0.7
4.2
NA
-31.2%
Commentary: Jun’25 shows explosive YoY recovery (last year had losses), but QoQ softness from a high Mar’25 base. Annualised EPS = ₹11.6 → P/E ~71x. Investors clearly expect “Divi’s 2.0,” not a Hyderabad service shop.
5. Valuation – Fair Value Range Only
Method 1: P/E Multiple
EPS (annualised Jun’25) = ₹11.6
Assign range 25–35x (sector peers like Divi’s ~70x, Cipla ~24x).
Fair value = ₹290 – ₹405
Method 2: EV/EBITDA
EV = ₹17,100 Cr, EBITDA (TTM) = ₹500 Cr
EV/EBITDA = 34x vs peers 15–20x
Fair value = ₹7,500 – ₹10,000 Cr EV → ₹360 – ₹480/share
